CN111165826A - Probiotic composition for improving renal function health - Google Patents
Probiotic composition for improving renal function health Download PDFInfo
- Publication number
- CN111165826A CN111165826A CN202010021911.8A CN202010021911A CN111165826A CN 111165826 A CN111165826 A CN 111165826A CN 202010021911 A CN202010021911 A CN 202010021911A CN 111165826 A CN111165826 A CN 111165826A
- Authority
- CN
- China
- Prior art keywords
- kidney
- renal function
- vitamin
- probiotics
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 33
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 32
- 230000003907 kidney function Effects 0.000 title claims abstract description 29
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 22
- 230000036541 health Effects 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title abstract description 15
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 23
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 15
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 15
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 14
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 9
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 9
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 9
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 7
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 7
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 7
- 229940035035 polydextrose Drugs 0.000 claims abstract description 7
- 239000001259 polydextrose Substances 0.000 claims abstract description 7
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 6
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims abstract description 6
- 229920002907 Guar gum Polymers 0.000 claims abstract description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 6
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 6
- 229940004120 bifidobacterium infantis Drugs 0.000 claims abstract description 6
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 6
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 6
- 235000010417 guar gum Nutrition 0.000 claims abstract description 6
- 229960002154 guar gum Drugs 0.000 claims abstract description 6
- 239000000665 guar gum Substances 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229940109529 pomegranate extract Drugs 0.000 claims abstract description 4
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 3
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 3
- 229960003237 betaine Drugs 0.000 claims abstract description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 3
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract 2
- 241000894006 Bacteria Species 0.000 claims description 29
- 239000000047 product Substances 0.000 claims description 19
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- 229940001941 soy protein Drugs 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
- 244000197580 Poria cocos Species 0.000 claims description 6
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 5
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 5
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 5
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims description 5
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- 235000015468 Lycium chinense Nutrition 0.000 claims description 4
- 241001593968 Vitis palmata Species 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 235000005282 vitamin D3 Nutrition 0.000 claims description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 4
- 239000011647 vitamin D3 Substances 0.000 claims description 4
- 229940021056 vitamin d3 Drugs 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 229940038487 grape extract Drugs 0.000 claims description 3
- 230000001976 improved effect Effects 0.000 claims description 3
- 241000282461 Canis lupus Species 0.000 claims description 2
- 244000241872 Lycium chinense Species 0.000 claims description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims 3
- 229940099352 cholate Drugs 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 210000004211 gastric acid Anatomy 0.000 claims 1
- 210000004051 gastric juice Anatomy 0.000 claims 1
- 241000411851 herbal medicine Species 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 239000011241 protective layer Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 26
- 230000006870 function Effects 0.000 abstract description 22
- 239000003814 drug Substances 0.000 abstract description 13
- 235000019710 soybean protein Nutrition 0.000 abstract description 13
- 235000013305 food Nutrition 0.000 abstract description 11
- 230000036039 immunity Effects 0.000 abstract description 9
- 240000005717 Dioscorea alata Species 0.000 abstract description 6
- 235000004879 dioscorea Nutrition 0.000 abstract description 6
- 230000003647 oxidation Effects 0.000 abstract description 6
- 238000007254 oxidation reaction Methods 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 6
- 244000269722 Thea sinensis Species 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 5
- 235000013406 prebiotics Nutrition 0.000 abstract description 5
- 208000037157 Azotemia Diseases 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 4
- 235000017784 Mespilus germanica Nutrition 0.000 abstract description 4
- 244000182216 Mimusops elengi Species 0.000 abstract description 4
- 235000000560 Mimusops elengi Nutrition 0.000 abstract description 4
- 235000001188 Peltandra virginica Nutrition 0.000 abstract description 4
- 235000007837 Vangueria infausta Nutrition 0.000 abstract description 4
- 229930003270 Vitamin B Natural products 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 230000009467 reduction Effects 0.000 abstract description 4
- 208000009852 uremia Diseases 0.000 abstract description 4
- 235000019156 vitamin B Nutrition 0.000 abstract description 4
- 239000011720 vitamin B Substances 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 229930003316 Vitamin D Natural products 0.000 abstract description 2
- 235000019166 vitamin D Nutrition 0.000 abstract description 2
- 239000011710 vitamin D Substances 0.000 abstract description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract description 2
- 229940046008 vitamin d Drugs 0.000 abstract description 2
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000009569 green tea Nutrition 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 36
- 208000020832 chronic kidney disease Diseases 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- 230000009286 beneficial effect Effects 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- 208000017169 kidney disease Diseases 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241000186000 Bifidobacterium Species 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 6
- 230000024924 glomerular filtration Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 201000008383 nephritis Diseases 0.000 description 6
- 235000002723 Dioscorea alata Nutrition 0.000 description 5
- 235000007056 Dioscorea composita Nutrition 0.000 description 5
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 5
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 5
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 5
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 5
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 5
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 5
- 241000736262 Microbiota Species 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001434 glomerular Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 235000021120 animal protein Nutrition 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 235000001055 magnesium Nutrition 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 206010021027 Hypomagnesaemia Diseases 0.000 description 3
- 208000000913 Kidney Calculi Diseases 0.000 description 3
- 241000186605 Lactobacillus paracasei Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010029148 Nephrolithiasis Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 206010041497 Spermatorrhoea Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 208000013038 Hypocalcemia Diseases 0.000 description 2
- 208000019025 Hypokalemia Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 206010023421 Kidney fibrosis Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010062237 Renal impairment Diseases 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000000705 hypocalcaemia Effects 0.000 description 2
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N methylguanidine Chemical compound CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 2
- 235000015816 nutrient absorption Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- WGNAKZGUSRVWRH-UHFFFAOYSA-N p-cresol sulfate Chemical compound CC1=CC=C(OS(O)(=O)=O)C=C1 WGNAKZGUSRVWRH-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 208000024896 potassium deficiency disease Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000009193 Caveolin Human genes 0.000 description 1
- 108050000084 Caveolin Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710094902 Legumin Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000013901 Nephropathies and tubular disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 125000001511 cyclopentyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108010083391 glycinin Proteins 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 208000037978 tubular injury Diseases 0.000 description 1
- 230000010024 tubular injury Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A probiotic composition for improving renal function health is provided. The invention relates to a probiotic composition capable of improving renal function, wherein 10% -30% of soybean protein powder, 10% -20% of fructo-oligosaccharide, 7% -15% of polydextrose, 5% -12% of maltodextrin, 1% -3% of guar gum, 1% -1% of lactobacillus acidophilus TYCA 060.5%, 3% -1% of bifidobacterium infantis BLI-020.5%, 1% -1% of bifidobacterium bifidum VDD 0880.5% (note that the strains are freeze-dried powder), 2% -4% of tuckahoe, 2% -4% of medlar, 2% -4% of yam, 0.05% -1% of green tea polyphenol, 3% -8% of pomegranate extract, 7% -15% of betaine, 0.13% -0.21% of magnesium sulfate, 30.000001% -0.000002% of vitamin D, and 60.0007% -0.0022% of vitamin B. Through the organic combination of the nutrients, the nutrition plays a role in coordination and synergism, the probiotics utilizes prebiotics by means of the traditional medicine and food homology and the action of plant effective components in vivo, improves and improves the self functions, particularly the renal function, maintains the micro-ecological balance of the human body through an intestine-brain-kidney axis, prevents and relieves failure, chronic diseases or uremia caused by renal function reduction, and has the functions of resisting oxidation, detoxifying and regulating immunity.
Description
Technical Field
The invention relates to a composition containing other beneficial components and nutrients, which utilizes the effect of probiotics to improve and enhance the renal function of organisms and maintain the normal microbiota and flora balance of human bodies.
Background art:
once a person grows, the microbe can contact with parent microbes and external microbes, and can quickly form normal microbial communities in the body and on the body surface. These microorganisms are the existence of human life and are a component of defense against insults. From birth to death, humans are kept in microecological balance with normal microorganisms in and on their bodies. This dynamic balance is a physiological combination of the normal microbiota formed during long-term historical evolution with the host at different developmental stages, being a balance at the cellular or molecular level. Some diseases occur when the normal microbial flora of the human body is changed and the physiological functions of the host are changed. The microecological imbalance refers to a state in which the microecological balance between normal microorganisms and their hosts is changed from physiological to pathological combinations.
The content of feces per gram in normal large intestine is 107~1012In the normal bacterial spectrum of the excrement, the normally living bacteria account for more than 90 percent, wherein common escherichia coli and enterococcus respectively account for half, the number of the passing bacteria (such as coliform bacteria, aerogenic bacillus, proteus, pseudomonas aeruginosa and pneumonia bacillus) does not exceed 10 percent, and the number of the bacillus and the microzyme is not more than 10 percent of the total bacteria although the bacillus and the microzyme are also called as normally living bacteria. The flora is combined according to a certain proportion, restricted and dependent with each other, and forms a certain ecological balance in quality and quantity. If the internal and external environments of the body occurIf the excessive bacteria (including bypath bacteria, spore bacteria and yeast) are propagated by more than 40% of the normal value, the decomposition of the intestinal food is disturbed, and the symptom of unbalanced intestinal flora appears, which is clinically manifested as acute or chronic diarrhea.
For example, the unbalance of normal flora can cause gastrointestinal dysfunction and diarrhea, affect the whole body through blood circulation, and further cause diseases such as renal calculus, nephritis and even renal failure through an intestine-kidney axis.
Relevant epidemiological data show that the incidence rate of Chronic Kidney Disease (CKD) in the people of China is about 11-13%, and according to the data, CKD patients in China exceed 1 hundred million. The complex physiological functions of the kidney and its unique tissue structure make it vulnerable to injury in a variety of situations. Nephritis refers to a group of kidney diseases which are mediated by immunity, involved in inflammatory mediators (such as complement, cytokines, active oxygen, etc.), and finally cause inflammatory changes of the inherent tissues of the kidney, and cause different degrees of renal function decline, and can be caused by various causes. Non-immune and non-inflammatory mechanisms are also involved in the chronic process. The method is characterized by comprising the following steps: glomerular permeability changes to proteins and cells; kidney dysfunction in water, electrolytes, acid-base balance and blood pressure regulation; impaired glomerular filtration function. Related studies have shown that nephritis may be associated with viral, bacterial infections, other disease-inducing, genetic factors, drugs and autoimmune disorders.
In recent 20 years, with the rapid development of microecology, the microecological preparation has been widely applied to clinic, and has great effects on maintaining or adjusting the microecological balance of human bodies, treating diseases related to microecological imbalance and promoting health. Scientists in various countries have been intensively studying lactobacilli and bifidobacteria, and have found some new functions of the lactobacilli and the bifidobacteria and the intestinal physiological symbiosis bacteria (especially the lactobacilli and the bifidobacteria are innovative in the field of kidney disease treatment), and have rapidly carried out bioengineering development in food and medicine industries, and have made remarkable progress. The function of dietary fiber is greatly concerned in the field of nutrition, and the physicochemical property and physiological action of the dietary fiber and the relationship between human health and diseases are extensively and deeply researched. The homology of medicine and food is one of the most valuable contributions to human beings in the original Chinese medicine, the traditional Chinese medicine always emphasizes that the medicine therapy is inferior to the food therapy, the food therapy is the best choice for modern people to pursue truthful and healthy diet, and certain food materials are proved to have prebiotic functions by research; at present, only different products prepared from single prebiotics, lactobacillus acidophilus and bifidobacterium exist in the market, but the prepared health combination mainly comprising probiotics and assisting medicinal and edible food materials and plant effective substances for improving renal function does not have similar products.
Disclosure of Invention
The invention aims to develop a composite probiotic (lactobacillus acidophilus, bifidobacterium infantis, bifidobacterium bifidum, lactobacillus paracasei and lactobacillus reuteri), which is a composition prepared and processed by adopting active biological components (soybean protein and polyphenol), prebiotics (fructo-oligosaccharide and polydextrose), a traditional medicine and food homologous formula (tuckahoe, medlar and yam), key mineral substances, vitamins and the like, through the organic combination of the nutrients, the product has various functional components which are blended into the product, the components are mutually matched and have synergistic action, through the in vivo action of the probiotic on the traditional medicine and food homologous beneficial components and plant effective components, the product can improve and improve the self function, particularly the kidney function, maintain the normal and balance of the microbiota of a human body, prevent and treat uremia or failure and chronic kidney disease caused by the decline of the kidney function, resisting oxidation, resisting aging, regulating immunity, and removing toxic substances.
The technical scheme of the invention is as follows:
according to the weight ratio:
isolated soy protein | 10~30% |
Fructo-oligosaccharide | 10~20% |
Polydextrose | 7~15% |
Maltodextrin | 5~12% |
Guar gum | 1~3% |
Lactobacillus acidophilus | 0.5~1% |
Bifidobacterium infantis | 0.5~1% |
Bifidobacterium bifidum | 0.5~1% |
Poria cocos (Schw.) wolf | 2~4% |
Chinese wolfberry fruit | 2~4% |
Chinese yam | 2~4% |
Tea polyphenols | 0.05~0.1% |
Pomegranate extract | 3~8% |
Red grape extract | 3~8% |
Betaine | 7~15% |
Magnesium sulfate | 0.13~0.21% |
Vitamin D3 | 0.000001%~0.000002% |
Vitamin B6 | 0.0007~0.0022% |
The production process comprises the following steps:
all operations should be performed in a clean and dry environment to ensure the quality of the product.
Weighing the corresponding materials according to the proportion, and mixing the materials uniformly in sequence. Each bag is 3g, and the bags are measured and packaged. Adding the materials according to the weight ratio, mixing, granulating, drying, grading, inspecting, packaging and obtaining the finished product, namely the solid beverage powder with the function of tonifying the kidney.
The product quality requirement is as follows: the content of Bifidobacterium is not less than 1 × 109Per gram; the content of lactobacillus is not less than 1 × 109Per gram.
And (3) product packaging: 3 g/bag; the recommended daily consumption is: 1-2 bags per day contain probiotic combination main components and instructions capable of improving renal function health:
isolated soy protein:
the soybean protein is the main part of soybean, is only dissolved in salt solution or other polar solution, and belongs to globulins (globulins). Crude soy protein is a mixture of different proteins, and the composition of soy protein is studied by centrifugal sedimentation and immunological methods to classify soy protein into 4 classes, wherein 11s of legumin (glycinin) and 7s of pisilin (conglycinin), both of which account for about 70% of soy protein, are the major functional components of soy protein. The soybean protein is rich in amino acids, and the rest of 8 kinds of essential amino acids for human body are almost similar to animal protein except for slightly lower methionine, and contain more lysine. Although the soybean protein contains little methionine, the soybean protein does not contain cholesterol, and isoflavone which is a special physiological active substance has the function of lowering cholesterol. The soybean protein beverage is easier to digest and absorb than milk, the milk is easy to form large and hard blocks after entering the stomach, and the soybean milk is formed into small slices after entering the stomach, is soft and not hard, and can be digested and absorbed more easily.
The observed data of chronic kidney disease (hereinafter abbreviated as CKD) mainly include blood creatinine, blood triglyceride, blood cholesterol, blood calcium and blood phosphorus. The study of soybean protein has been intensive since 2000, and the misconception that renal patients strictly prohibit the ingestion of vegetable proteins has gradually changed. Multiple randomized controlled experiments or meta-analyses demonstrated that soy protein has a protective effect on serum creatinine and serum phosphorus in CKD patients compared to animal protein, and also suggests that ingestion of soy protein significantly reduces serum triglyceride levels. The change of nitric oxide and caveolin protein in kidney tissue after soybean protein diet may be involved in kidney protection mechanism. And the effect of the soybean protein on the kidney disease is multidirectional, and the soybean protein can relieve almost all uremia symptoms except anemia. In part of polycystic kidney models in recent years, the soybean protein has better effect of delaying the progress of CRF (chronic renal failure) than animal protein, has lower blood urea nitrogen than the animal protein, and has no obvious change in serum amino acid level.
Fructooligosaccharides and polydextrose:
oligosaccharides (oligosaccharides) are low-degree polymeric saccharides having a linear chain or branched chain formed by connecting 2 to 10 monosaccharides by glycosidic bonds, and functional oligosaccharides have many excellent characteristics, physiological activities and health-care functions. The fructo-oligosaccharide has the function of resisting decayed teeth, is not digested and absorbed by human bodies, is not utilized by most of intestinal putrefying bacteria, inhibits the growth of harmful bacteria, can be selectively utilized by beneficial bacteria of the human bodies, is called prebiotics and is also an excellent bifidobacterium proliferation factor. Regulating intestinal homeostasis; can promote the absorption and utilization of trace elements of iron and calcium to prevent osteoporosis; can reduce liver toxin, can generate anticancer organic acid in intestines, and has obvious cancer prevention function; and the taste is pure, fragrant, sweet and delicious, and has the fragrance similar to fat and the smooth and greasy feeling of mouth feel.
Meanwhile, research finds that the utilization PI value of the levan FOS reaches above 0.6 aiming at the lactobacillus paracasei and the lactobacillus acidophilus used in the component, and homofermentation generates a large amount of lactic acid, which shows that the levan utilization proliferation and acid production capability are outstanding. Has good physiological function and can improve the immunity of the organism.
Polydextrose can adsorb organic molecules such as bile acid and cholesterol mutagen, inhibit the increase of Total Cholesterol (TC) concentration, reduce the synthesis and absorption of cholic acid and salts, reduce the level of human plasma and cholesterol, and has positive effects and significance in preventing renal calculus and relieving renal burden.
Guar gum:
guar gum is a soluble dietary fiber and has the main functions of:
1. promoting colon function, and preventing colon cancer. The retention time of the excrement in the colon can be shortened, and the excrement quantity is increased, so that the toxin is diluted, namely the kidney burden is reduced.
2. Reduce the dependence of renal type diabetes patients on insulin and drugs. Diabetic patients are more common with hyperlipidemia, and lipid metabolism disorder can cause adverse consequences. The dietary fiber not only helps to regulate lipid metabolism, but also inhibits amylase action, delays carbohydrate absorption, and lowers fasting and postprandial blood glucose levels.
3. Preventing energy excess, and controlling obesity. Because of its strong water absorbing capacity or water binding capacity, it can increase the volume of food and make people feel full, thus it can reduce the amount of food intake, and is beneficial to controlling weight and preventing obesity.
Lactobacillus acidophilus, bifidobacterium infantis, bifidobacterium bifidum:
the three are all inherent beneficial bacteria in human body, can improve organism, intestines and stomach, kidney function, whet appetite, help digestion and absorption. It has nourishing and protecting effects, and can inhibit intestinal putrefaction bacteria, food poisoning bacteria, pathogenic bacteria, etc. Research proves that the lactobacillus acidophilus is supplemented, so that the breeding of escherichia coli can be inhibited, harmful bacteria in gastrointestinal tracts can be reduced, gastrointestinal motility is promoted, and nutrient absorption is increased. In modern life, a large amount of beneficial bacteria in a human body are lost due to abuse of antibiotics, environmental pollution, poor dietary habits, disease attack and other factors. Therefore, there is a good way to supplement probiotics in daily life and to maintain intestinal health and also to influence the functions of other organs through the intestine-kidney axis.
The relevant health mechanisms are:
1. inhibiting saprophytic bacteria growth. The oral selected probiotic strains can increase the number of inherent live bacteria of lactobacillus and bifidobacterium and reduce the number of bacteroides, clostridium and enterobacteria, because the pH value of the intestinal tract is reduced by the acetic acid and lactic acid generated after the intestinal tract action of the probiotics, thereby achieving the purpose of inhibiting saprophytic bacteria. After saprophytic bacteria are inhibited, harmful substances such as indole, phenol, ammonia and the like in the human body are also obviously reduced.
2. The supply of vitamins is maintained. Not only can produce various vitamins (such as vitamin B group) for human body to utilize, but also can protect the supply of vitamins by inhibiting the decomposition of certain vitamins. For example, it can inhibit the decomposition of vitamin B1Or otherwise cause vitamin B in human body1And (4) lack.
3. The gut microbiota is linked to the endocrine, nervous and immune systems, regulating host homeostasis, including blood pressure and kidney function. The brain-gut-kidney axis is involved in the connections between these organs, which are mediated by autoregulation from the brain and signals from the brain and kidneys (e.g., immune products and microbial metabolites). Inflammation of gastric mucosa, increased intestinal permeability, altered bacterial phase, abnormal metabolism of bacterial flora, and increased harmful substances, which in turn may affect decreased glomerular filtration rate, increased proteinuria, and glomerular and tubular injury. The dysbiosis of the flora can cause the imbalance of immune response and inflammatory reaction, and the generation of inflammatory cytokines is enhanced; the fermentation of fed carbohydrates, proteins and bile acids changes, preferentially converting to the accumulation of noxious substances such as indoxyl sulfate, p-cresol sulfate and trimethylamine N-oxide. The benefit of probiotics is that through nutrition competition, antibacterial substances are produced and become dominant bacteria, and then intestinal barrier can be enhanced, mucosal immunity and inflammation can be enhanced, which is proved by multiple research reports together.
4. In animal experiments, the probiotic component helps to reduce blood pressure (slow kidney blockage), is effective at low doses, and is dose-dependent. Helps the weight recovery of CKD mice, and has dose dependence. And also helps to reduce the urea nitrogen and creatinine values in blood. The high dose is beneficial to improving abnormal urinary albumin caused by kidney inflammation in CKD mice. Simultaneously inhibit kidney inflammation and improve kidney fibrosis.
5. the probiotic component in vitro test is adopted to promote peripheral blood cells of human beings to secrete anti-inflammatory hormone IL-10 (TGF- β), which is helpful for inhibiting injury caused by excessive inflammation, has the immunoregulation effect, regulates Th1/Th2, leads the immunoreaction to tend to Th1, and avoids injury of chronic systemic inflammation to the body, strains in the formula all have the oxidation resistance, wherein, the antioxidation effect of infant bifidobacterium is excellent, the antioxidation capability of vitamin C is comparable to that of free radical removal, and the oxidative injury is avoided, other human clinical tests prove that the continuous consumption of the probiotic can delay the renal function deterioration and delay the trend of reduction of glomerular filtration rate (eGFR), CKD patients are easy to express higher amounts of IL-6, IL-8 and TNF- α, and the content of the cytokines in serum is reduced after 6 months or more, and particularly the IL-8 is reduced to the maximum extent.
6. Test example 1: mouse model, low dose group add bacterial powder combination 107CFU, high dose group add powder combination 109CFU, test time 6 weeks.
TABLE 1 improvement of blood pressure in CKD mice
TABLE 2 recovery of Kidney health
TABLE 3 Kidney function recovery
According to experimental data, the probiotic combination can obviously improve the hypertension condition of mice with induced chronic kidney disease, recover the normal body weight and the kidney weight of the mice, and can improve related renal function indexes through blood biochemical analysis, particularly the improvement condition of a high-dose group is more obvious, and the combination proves to have dose dependence.
7. Test example 2: human clinical trial, the experimental population is 44, and one granule containing 2.5X 10 is taken in the morning and evening7Probiotic capsules of CFU, test time 6 months.
TABLE 4 glomerular filtration rate in serum (eGFR)
The test period is more than 6 months, and the renal tubule filtration rate of 3 months and 6 months shows that the symptoms of patients with 3-5 stage chronic nephropathy are all moderate and are positively correlated with the taking time.
TABLE 5 Rate of delay of renal function deterioration (eGFR)
After 3 months of administration, up to 56.8% of patients improved, more after 6 months, 71.1% of patients improved, the rate increased by 14.3%, and the improvement amplitude was 1.25 times.
TABLE 6 improvement of borborygmus and flatulence in CKD patients
Poria/wolfberry/yam:
kidney damage is manifested in TCM as kidney qi deficiency, kidney yang deficiency and kidney yin deficiency. Generally, nephritis is caused by invasion of exogenous pathogenic factors to injure spleen and kidney, and the transportation function of spleen and the opening and closing function of kidney are damaged. For kidney yang deficiency, spleen and kidney qi deficiency or kidney yin deficiency, it is usually indicated that tuckahoe, yam and wolfberry fruit are selected as the combination of the commonly used prescriptions.
Tuckahoe, poria cocos: sweet and bland in flavor and mild in nature. It enters heart, lung, spleen and kidney meridians. Induce diuresis and drain dampness, invigorate spleen and calm heart. Can be used for treating edema, oliguria, palpitation due to phlegm and fluid retention, spleen deficiency, anorexia, loose stool, and diarrhea. Pachyman can prevent renal calculus formation and renal interstitial fibrosis, improve creatinine, increase albumin concentration, and delay renal failure.
Chinese yam: sweet and mild in taste. Enter lung, spleen and kidney meridians. To invigorate the spleen, tonify the lung, strengthen the kidney and replenish vital essence. It is indicated for diarrhea due to spleen deficiency, chronic dysentery, cough due to asthenia, diabetes, spermatorrhea, leukorrhagia, and frequent micturition. Tonify spleen and stomach, promote the production of body fluid and nourish lung, tonify kidney and astringe essence. Can be used for treating spleen deficiency, anorexia, chronic diarrhea, lung deficiency, cough, asthma, spermatorrhea, leukorrhagia, frequent micturition, and diabetes due to deficiency heat. The Chinese yam contains rich dehydroepiandrosterone, is an important active substance in human body life activity, and is a derivative of cyclopentane polyhydrophenanthrene. Its main health-care functions are resisting senility, strengthening immunity and improving new functions, so that the Chinese yam can be converted into sex hormone according to the requirements of human body, and can make human body retain vigorous energy, raise the capability of resisting diseases and accelerate the repair of damaged tissue. The main components of the yam also comprise yam protein polysaccharide which can eliminate free radicals and reduce the levels of urine protein, urea nitrogen and creatinine of diabetic nephropathy. Participate in the regeneration and repair of renal tubular epithelial cells and the reconstruction of renal tubular structures, and effectively protect the renal function.
Medlar: sweet and mild in taste. Enter liver and kidney meridians. Nourish kidney, moisten lung, tonify liver, improve vision. It is indicated for liver and kidney yin deficiency, soreness and weakness of waist and knees, dizziness, blurred vision, hyperdacryosis, cough due to asthenia, diabetes, and spermatorrhea. The lycium barbarum polysaccharide can resist free radicals and has an intervention effect on kidney injury. Animal experiments can also show that the medlar can protect the shape of glomerulus, the hardening rate of the glomerulus and the thickness of the glomerulus basement membrane and delay senility.
Polyphenols: tea polyphenols/pomegranate extract/red grape extract
Tea polyphenols are mostly EGCG, pomegranate polyphenols are mostly PCSE, and red grape polyphenols are mostly GSPE. The kidney is the organ which is most likely to generate active oxygen in the organism, and inflammation reaction, ischemia-reperfusion, diabetes and the like can induce the kidney to generate rich active oxygen to cause nephropathy. Once renal disease occurs, the normal balance of coagulation and fibrinolysis is disturbed, resulting in intravascular fibrin deposition and thrombosis, thereby promoting disease progression, and a drastic decline in renal function, ultimately leading to worsening renal disease. Polyphenols are well-known high-efficiency free radical scavengers and are also good immunomodulators. In scientific experiments, after polyphenol is taken, the compound has good diuretic effect, obviously reduces the contents of proteinuria, serum creatinine and urea nitrogen, and the mechanism of the compound is related to the increase of RPF and the reduction of filtration fraction. It has also been shown that tea improves glomerular filtration rate, a function which corresponds to impaired renal function. In addition, the tea polyphenol also has a better treatment effect on renal injury caused by cadmium, and can also protect renal cell apoptosis caused by chromium. Methylguanidine, the most toxic toxin in urine of current regimens, is significantly inhibited by polyphenols, i.e. by eliminating the vicious circle by improving the system microenvironment, thus inhibiting glomerular degeneration. Polyphenols can also effectively improve renal blood flow and glomerular basement membrane permeability and reduce thrombosis by reducing blood viscosity, preventing platelet adhesion and increasing anticoagulation, which has important positive effects on preventing the progression and deterioration of renal disease.
Magnesium:
under normal conditions, the balance of magnesium ions in a kidney is mainly regulated by the kidney, the function of the kidney for preserving magnesium is considered to be good, hypomagnesemia is rare, but in recent years, hypomagnesemia is not rare, hypokalemia and hypocalcemia are often accompanied, hypocalcemia can be caused during hypomagnesemia, the capacity of the kidney for preserving potassium is reduced, and hypokalemia occurs, diabetes patients have important significance for DN early diagnosis, prognosis and the like in monitoring serum magnesium level.
Vitamin D3:
can promote calcium absorption and reduce osteoporosis due to abnormal mineral absorption caused by CKD. And has remarkable effect on treating secondary hyperparathyroidism in chronic renal failure and protecting kidney and kidney. Can inhibit development of renal diseases by inhibiting multiple pathological processes in the development process of renal diseases and inhibiting glomerular and tubulointerstitial fibrosis through multiple ways.
Vitamin B6:
is helpful for protein metabolism and utilization, and the deficiency of vitamin B6 can aggravate kidney damage and reduce Glomerular Filtration Rate (GFR) ability. Can inhibit conversion of ketoamine into AGEs and oxidative stress, reduce AGEs formation in glomerular tissue, and prevent early diabetic nephropathy.
In conclusion, the probiotic composition containing the health-improving probiotic has the effects of improving the body, intestines, stomach and kidney functions, maintaining the normal microbiota of a human body, resisting oxidation, aging and inflammation, improving the immunity, strengthening the body, detoxifying and protecting the kidney and the like.
The invention has the technical advantages that:
the invention develops a probiotic compound composition beneficial to renal function health, which is prepared and processed by adopting soybean protein, fructo-oligosaccharide, polydextrose, guar gum, lactobacillus acidophilus, bifidobacterium infantis, bifidobacterium bifidum, lactobacillus reuteri, lactobacillus paracasei, medicinal and edible homologous components, polyphenols, magnesium, vitamin D3, vitamin B6 and the like, through the organic combination of the nutrients, the product has various functional components which are blended into the product, the components cooperate with each other and act synergistically, and the traditional medicinal and edible beneficial components and plant effective components act in vivo through probiotics, so that the health-care tea can improve and improve the self function, particularly the renal function, maintain the normal microbiota and balance of a human body, prevent and treat uremia or failure caused by renal function reduction, resist oxidation and aging, adjust comprehensive immunity and detoxify.
The concrete points are as follows:
1. improving gastrointestinal function. A protective barrier is formed on the surface of the intestinal mucosa to resist the invasion and damage of harmful bacteria to the intestinal mucosa, acidic substances such as lactic acid, acetic acid and the like can be generated, an environment which is not beneficial to the growth of the harmful bacteria is created, the growth and the propagation of the harmful bacteria are inhibited, and the effect of regulating the intestinal flora is achieved.
2. Reduce the concentration of dimethylamine and nitrosodimethylamine and can reduce carcinogen in intestinal tract. Intake of 8X 109The probiotic group of CFU, serum uric acid decreased 3.37%. Intake of 16X 109The probiotic group of CFU, serum uric acid decreased 10.98%.
3. can regulate immunity (Th1/Th2), and relieve inflammation (IL-10, 8, THF- β), prevent body injury due to chronic systemic inflammation, and protect patients with chronic nephropathy.
4. Has antioxidant effect, and can scavenge free radicals in vivo and resist oxidation pressure.
5. Animal experiments prove that the traditional Chinese medicine composition can reduce the blood pressure of mice with chronic kidney diseases, is beneficial to restoring the health of the kidney and reducing inflammatory reaction.
6. Human body tests prove that the traditional Chinese medicine composition can help chronic nephrotic patients to delay renal function deterioration and improve the situations of borborygmus and flatulence caused by side effects of medication.
7. Has nourishing effect. Can improve the utilization rate of calcium, phosphorus and iron, promote the absorption of iron and vitamin D, generate vitamin K and vitamin B, and generate lactase to help digest lactose.
8. Recovering intestinal tract damaged by antibiotic. The antibiotic is an important factor causing the imbalance of the intestinal flora, kills harmful bacteria and a plurality of beneficial bacteria, supplements bifidobacteria and lactobacilli in time, and is very necessary for helping the intestinal tract to restore the flora balance and improving the nutrient absorption capacity.
Detailed Description
Example 1
The invention relates to a probiotic composition for improving renal function health, which is characterized by being a product prepared from the following raw materials in percentage by weight.
The formula is as follows:
according to the weight ratio
Example 2
The invention relates to a probiotic composition for improving renal function health, which is characterized by being a product prepared from the following raw materials in percentage by weight.
The formula is as follows:
according to the weight ratio
Example 3
The invention relates to a probiotic composition for improving renal function health, which is characterized by being a product prepared from the following raw materials in percentage by weight.
The formula is as follows:
according to the weight ratio
Claims (2)
1. A probiotic combination for improving renal function health, comprising: the product is prepared from the following raw materials in percentage by weight:
2. The invention uses a series of key technologies of integration innovation and industrialization production, such as microcapsule, biological enzymolysis, prehydrolysis SBE, spray drying, freeze drying and the like to form a final product. In particular, the microencapsulation protection technology ensures that more than 2 embedding protective layers are arranged outside the freeze-dried bacteria powder, thereby effectively solving the problem of inactivation of probiotics by high temperature and gastric acid strong acid in the process of oral administration or water dissolution; the probiotic bacteria are uniformly mixed with the Chinese herbal medicine extract extracted by the biological enzymolysis or prehydrolysis SBE technology so as to solve the problem of coexistence of multiple probiotics and medicine-food homologous components of a common product, have certain high temperature resistance and strong acid resistance, are favorable for the oral probiotics to smoothly pass through gastric juice to stay in intestinal tracts for field planting, and have the survival rate of over 93 percent through acid resistance and cholate resistance test, so that the product efficacy is greatly improved compared with similar products in the market.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010021911.8A CN111165826A (en) | 2020-01-09 | 2020-01-09 | Probiotic composition for improving renal function health |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010021911.8A CN111165826A (en) | 2020-01-09 | 2020-01-09 | Probiotic composition for improving renal function health |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111165826A true CN111165826A (en) | 2020-05-19 |
Family
ID=70620162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010021911.8A Pending CN111165826A (en) | 2020-01-09 | 2020-01-09 | Probiotic composition for improving renal function health |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111165826A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112471517A (en) * | 2020-11-26 | 2021-03-12 | 江西长通实业有限公司 | Protein powder and preparation process thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005032591A1 (en) * | 2003-09-30 | 2005-04-14 | Kibow Biotech, Inc. | Compositions and methods for augmenting kidney function |
CN1871031A (en) * | 2003-09-30 | 2006-11-29 | 基博生物技术公司 | Compositions and methods for augmenting kidney function |
CN101897729A (en) * | 2009-05-31 | 2010-12-01 | 金士力佳友(天津)有限公司 | Probiotic composition and preparation thereof |
CN104187612A (en) * | 2014-07-26 | 2014-12-10 | 胡安然 | Full-nutritional formula food for nephropathy |
US20160051600A1 (en) * | 2013-03-21 | 2016-02-25 | Nutrimentos Inteligentes, S.A. De C.V. | Gelatinous mixture of probiotics and prebiotics with synergic symbiotic action for treating chronic renal disease |
CN108936678A (en) * | 2018-08-08 | 2018-12-07 | 深圳极醇健康产业股份有限公司 | A kind of probiotics capsule and preparation method thereof |
-
2020
- 2020-01-09 CN CN202010021911.8A patent/CN111165826A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005032591A1 (en) * | 2003-09-30 | 2005-04-14 | Kibow Biotech, Inc. | Compositions and methods for augmenting kidney function |
CN1871031A (en) * | 2003-09-30 | 2006-11-29 | 基博生物技术公司 | Compositions and methods for augmenting kidney function |
CN101897729A (en) * | 2009-05-31 | 2010-12-01 | 金士力佳友(天津)有限公司 | Probiotic composition and preparation thereof |
US20160051600A1 (en) * | 2013-03-21 | 2016-02-25 | Nutrimentos Inteligentes, S.A. De C.V. | Gelatinous mixture of probiotics and prebiotics with synergic symbiotic action for treating chronic renal disease |
CN104187612A (en) * | 2014-07-26 | 2014-12-10 | 胡安然 | Full-nutritional formula food for nephropathy |
CN108936678A (en) * | 2018-08-08 | 2018-12-07 | 深圳极醇健康产业股份有限公司 | A kind of probiotics capsule and preparation method thereof |
Non-Patent Citations (3)
Title |
---|
李占彦: "《寻苗枸杞香》", 30 June 2016, 阳光出版社 * |
李曼莎等: "益生菌与药食同源植物的协同作用", 《食品工业》 * |
范辰玉: "甜菜碱对高尿酸血症小鼠肾损伤的保护作用及其机制研究", 《中国优秀硕士学位论文全文数据库(电子期刊)》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112471517A (en) * | 2020-11-26 | 2021-03-12 | 江西长通实业有限公司 | Protein powder and preparation process thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6203797B1 (en) | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome | |
EP1675617B1 (en) | Compositions for augmenting kidney function | |
WO2022016774A1 (en) | Composition beneficial for regulating intestinal tract, promoting digestion and improving constipation, and preparation method therefor | |
CN107594279A (en) | A kind of probiotic powder solid beverage and preparation method thereof | |
CN100542430C (en) | A kind of nutrition albumen powder that contains profitable probliotics | |
KR101539382B1 (en) | Food composition for improvement of bowel function and relief of constipation | |
CN104187611A (en) | Total nutrient formula food for gastrointestinal malabsorption | |
CN104187708A (en) | Total-nutrient formulated food for patients with diabetes | |
CN105029447A (en) | Sea-fish oligopeptide powder containing activated probiotics | |
CN108968058A (en) | It is a kind of improve enteron aisle probiotics enzyme composition and application | |
CN114045233B (en) | Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof | |
CN104223074A (en) | Total-nutrition formula food for preventing constipation | |
CN111227261A (en) | Prebiotic composition and application thereof | |
CN104996994A (en) | Chronic obstructive pulmonary disease specific full nutritional formula food | |
CN104839683A (en) | Medical formula food for people with constipation | |
CN108968037A (en) | Senile dementia full nutrition formula food | |
CN115736142A (en) | Formula and preparation process of prebiotics prune fiber fruit drink | |
JP2016069317A (en) | Inhibitors that inhibit progression of renal failure, prophylactics of renal failure, and inhibitors of indoxyl sulfate production | |
JPH03151854A (en) | Composition for improving intestinal environment | |
CN107647410A (en) | A kind of probiotic powder of compound proportioning and preparation method thereof | |
WO2024149132A1 (en) | Probiotic protein multivitamin and preparation method therefor | |
CN115868582A (en) | Pig feed additive for improving intestinal health and pig feed | |
CN111165826A (en) | Probiotic composition for improving renal function health | |
CN105639393A (en) | Ginseng probiotics food capable of improving fatigue resistance of human bodies | |
CN104839673A (en) | Medical formula food for people with renal failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200519 |